Fulgent Genetics has acquired Inform Diagnostics from Avista Capital Partners, a private equity firm.
Inform Diagnostics is a pathology laboratory business in the U.S. Inform Diagnostics provides subspecialty pathologist–to–physician interaction with patient diagnoses in gastrointestinal pathology, dermatopathology, hematopathology, neuropathology, breast pathology, molecular diagnostics, and genitourinary pathology.
Fulgent Genetics provides COVID-19, molecular diagnostic, and genetic testing services. Fulgent Genetics serves hospitals, medical institutions, large corporations and patients.
Darryl Goss, Inform Diagnostics’ CEO, said, “Avista has been a true partner, guiding our strategic growth and supporting our organization, particularly as we navigated the challenges of the pandemic. Being acquired by Fulgent is an excellent outcome for our organization, allowing us to build upon the technologically driven initiatives started with Avista, and furthering our commitment to providing exceptional quality and service.”
Kirkland & Ellis served as legal counsel to Inform Diagnostics for the transaction.